There’s no question which drugmakers are leading the coronavirus vaccine race. Of the 48 candidates in clinical testing, 11 are in late-stage clinical studies, according to the World Health Organization.
We can whittle this list down further for U.S. investors. Only six public companies with late-stage COVID-19 vaccine candidates trade on U.S. stock exchanges. Some investors will attempt to pick the stock they deem most likely to be the biggest winner from among this group.
However, there is another potential approach: buying a basket of late-stage coronavirus vaccine stocks. Could this be a better strategy for investors?
Filling the basket
Two late-stage COVID-19 vaccines appear to be the closest to potentially reaching the U.S. market. Pfizer and BioNTech announced great efficacy results for